Novartis has agreed to buy Regulus Therapeutics for up to $1.7 billion, giving the Swiss drugmaker access to an experimental ...

After announcing successful trial results for its lead mRNA treatment earlier this year, Regulus Therapeutics agreed to be acquired by Novartis. 1 This will add the potential kidney disease treatment ...

Novartis AG has agreed to buy U.S. biotech firm Regulus Therapeutics Inc. in a deal that could be valued at up to $1.7 billion. The Swiss company will pay $7 a share in cash up-front through a ...

Novartis NOVN1.25%increase; green up pointing triangle has agreed to acquire Regulus Therapeutics RGLS 0.25%increase; green up pointing triangle for a total equity value of up to roughly $1.7 billion.

Regulus Therapeutics Inc. (NASDAQ:RGLS) announced some great news today, which is that it would be acquired by Novartis AG (NVS) for $7 per share in cash. However, there is room for additional ...

Novartis plans to acquire clinical stage biotech Regulus Therapeutics in a deal worth up to $1.7 billion. Under the terms announced April 30, the Swiss drugmaker will make an upfront payment of $ ...

Regulus is a clinical-stage biopharmaceutical company developing microRNA therapeutics for severe renal disease and autosomal dominant polycystic kidney disease (ADPKD). Also Read: Novartis Q1 ...

Shares of Regulus surged nearly 15% to $3.86 in premarket trading. Under terms of the deal, Novartis would pay Regulus upfront $7 per share in cash, or about $800 million, which represents a ...